These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 36274215)
41. Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer. Dong Y; Zhu Y; Zhuo M; Chen X; Xie Y; Duan J; Bai H; Hao S; Yu Z; Yi Y; Guan Y; Yuan J; Xia X; Yi X; Wang J; Wang Z Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428744 [TBL] [Abstract][Full Text] [Related]
42. Tumor mutational burden and efficacy of chemotherapy in lung cancer. Song J; Yan Y; Chen C; Li J; Ding N; Xu N; Bao H; Zhang X; Hong Q; Zhou J; Shao YW; Song Y; Tong L; Hu J Clin Transl Oncol; 2023 Jan; 25(1):173-184. PubMed ID: 35995891 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. Yamaguchi O; Imai H; Minemura H; Suzuki K; Wasamoto S; Umeda Y; Osaki T; Kasahara N; Uchino J; Sugiyama T; Ishihara S; Ishii H; Naruse I; Mori K; Kotake M; Kanazawa K; Minato K; Kagamu H; Kaira K Cancer Chemother Pharmacol; 2020 Apr; 85(4):761-771. PubMed ID: 32193618 [TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354 [TBL] [Abstract][Full Text] [Related]
45. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer]. Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161 [No Abstract] [Full Text] [Related]
46. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Peters S; Dziadziuszko R; Morabito A; Felip E; Gadgeel SM; Cheema P; Cobo M; Andric Z; Barrios CH; Yamaguchi M; Dansin E; Danchaivijitr P; Johnson M; Novello S; Mathisen MS; Shagan SM; Schleifman E; Wang J; Yan M; Mocci S; Voong D; Fabrizio DA; Shames DS; Riehl T; Gandara DR; Mok T Nat Med; 2022 Sep; 28(9):1831-1839. PubMed ID: 35995953 [TBL] [Abstract][Full Text] [Related]
47. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy. Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126 [TBL] [Abstract][Full Text] [Related]
48. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096 [TBL] [Abstract][Full Text] [Related]
49. Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors. Yu J; Park R; Miao R; Imanirad I; Shahzad M; Laborde JM; Knepper TC; Walko CM; Kim R J Immunother; 2024 Nov-Dec 01; 47(9):378-383. PubMed ID: 39012081 [TBL] [Abstract][Full Text] [Related]
50. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062 [TBL] [Abstract][Full Text] [Related]
51. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study. Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB. He J; Kalinava N; Doshi P; Pavlick DC; Albacker LA; Ebot EM; Tukachinsky H; Pratt J; Fusaro G; Oxnard GR; Green G; Fabrizio D; Baden J J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38035725 [TBL] [Abstract][Full Text] [Related]
54. Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer. Gao G; Cui L; Zhou F; Jiang T; Wang W; Mao S; Wu F; Jiang F; Zhang B; Bei T; Xie W; Zhang C; Zhang H; Gao C; Zhao X; Bai Y; Zhou C; Ren S Int J Cancer; 2023 Jan; 152(1):79-89. PubMed ID: 36062503 [TBL] [Abstract][Full Text] [Related]
55. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China. Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464 [TBL] [Abstract][Full Text] [Related]
56. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682 [TBL] [Abstract][Full Text] [Related]
57. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative. Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661 [TBL] [Abstract][Full Text] [Related]
58. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726 [TBL] [Abstract][Full Text] [Related]
59. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients. Hu X; Guo J; Shi J; Li D; Li X; Zhao W BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743 [TBL] [Abstract][Full Text] [Related]
60. Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than Tian T; Li Y; Li J; Xu H; Fan H; Zhu J; Wang Y; Peng F; Gong Y; Du Y; Yan X; He X; Cali Daylan AE; Pircher A; Neibart SS; Okuma Y; Hong MH; Huang M; Lu Y Transl Lung Cancer Res; 2024 Apr; 13(4):861-874. PubMed ID: 38736501 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]